News
Select year:
2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016
Click here for announcements regarding managers transactions.
Click here for news in Danish.
December 09, 2021 | Company Announcements
Bavarian Nordic A/S - Registration of Share Capital Increase of 6,373,680 New Shares CompletedDecember 06, 2021 | Company Announcements
Bavarian Nordic A/S Announces Completion of Directed Issue of 6,373,680 New Ordinary SharesDecember 06, 2021 | Company Announcements
Bavarian Nordic A/S Launches Offering of up to 6,373,680 New Shares in a Directed Issue December 06, 2021 | Company Announcements
Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital BaseDecember 05, 2021 | Company Announcements
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine CandidateNovember 26, 2021 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseNovember 12, 2021 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Nine Months of 2021September 24, 2021 | Company Announcements
Bavarian Nordic’s COVID-19 Funding Agreement with the Danish Ministry of Health Receives Final Approval from Parliament September 08, 2021 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseSeptember 01, 2021 | Company Announcements
Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine CandidateAugust 25, 2021 | Company Announcements
Bavarian Nordic Announces First Half 2021 Results August 23, 2021 | Company Announcements
Bavarian Nordic Receives Funding from the Danish Ministry of Health to Advance the Development of COVID-19 Booster VaccineAugust 23, 2021 | Company Announcements
Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine August 09, 2021 | Company Announcements
Bavarian Nordic Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine June 10, 2021 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseJune 02, 2021 | Company Announcements
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back ProgramMay 27, 2021 | Company Announcements
Bavarian Nordic Launches Share Buy-Back Program to Hedge Incentive Scheme ObligationsMay 27, 2021 | Company Announcements
Bavarian Nordic Announces Interim Results for the First Three Months of 2021May 27, 2021 | Company Announcements
Bavarian Nordic Announces Marketing and Distribution Agreement with Dynavax to Launch HEPLISAV B® Hepatitis B Vaccine in Germany April 29, 2021 | Company Announcements
Bavarian Nordic Reports New Preclinical Data for COVID-19 Vaccine Confirming Potential for Broad Protection against SARS-CoV2 VariantsApril 20, 2021 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held April 20, 2021April 06, 2021 | Company Announcements
Bavarian Nordic Receives Order to Manufacture Additional Ebola Vaccines March 29, 2021 | Company Announcements
Bavarian Nordic A/S – Notice Convening Ordinary General MeetingMarch 26, 2021 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseMarch 26, 2021 | Company Announcements
Bavarian Nordic Announces the Resignation of Tommi Kainu as EVP and Chief Business Officer